ROS1-Positive Non-small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

ROS1-Positive Non-small Cell Lung Cancer Market Outlook

Thelansis’s “ROS1-Positive Non-small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ROS1-Positive NSCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

ROS1-Positive Non-small Cell Lung Cancer Overview

ROS1-positive non-small cell lung cancer (NSCLC) is a subtype characterized by a genetic alteration involving the ROS1 gene. This gene codes for a receptor tyrosine kinase that plays a role in cell growth and proliferation. When the ROS1 gene undergoes rearrangement or fusion with another gene, it can lead to abnormal activation of the ROS1 protein, resulting in uncontrolled cell growth and cancer development. The precise cause of ROS1 rearrangements in NSCLC remains poorly understood. However, similar to other genetic changes in cancer, it is thought to occur due to random mutations or exposure to specific environmental factors like tobacco smoke or occupational hazards such as asbestos. ROS1-positive NSCLC tends to exhibit a more aggressive behavior than other NSCLC forms, associated with a higher risk of metastasis (spreading to other body parts) and a poorer prognosis. However, they are more commonly found in specific patient subgroups, such as younger individuals, never-smokers, and those with adenocarcinoma histology. Currently, ROS1 is the target of several specific tyrosine kinase inhibitors (TKIs), with only two, crizotinib and entrectinib, having received approval from the Food and Drug Administration (FDA). Crizotinib, a low molecular weight orally administered TKI, inhibits ROS1, MET, and ALK and is considered the gold standard first-line treatment with demonstrated significant efficacy for lung cancers that harbor ROS1 gene rearrangements.

• ROS1 rearrangements are relatively rare, occurring in approximately 1-2% of NSCLC cases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: